Novo Nordisk

News

Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure

News

CHMP backs Novartis’ Fabhalta as first oral therapy for PNH

The March meeting of the EMA’s human medicines committee (CHMP) saw an approval recommendation for Novartis’ Fabhalta, on track to become the first oral monotherapy for ra

News

Heart claims unlock Medicare coverage of obesity drugs

Medicare has loosened restrictions on the reimbursement of obesity drugs, thanks to clinical data showing they can improve cardiovascular outcomes, but their price could b

News

FDA clears Wegovy’s label to include heart health benefits

Novo Nordisk’s Wegovy has been given a first-in-class approval by the FDA to reduce the risk of serious cardiovascular conditions in people who are overweight or obese.

News

Novo Nordisk’s oral amycretin tops Wegovy in obesity trial

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling

News

Novo Nordisk looks set to add another string to Ozempic bow

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabete

Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior

CHMP backs Novartis’ Fabhalta as first oral therapy for PNH

Heart claims unlock Medicare coverage of obesity drugs

FDA clears Wegovy’s label to include heart health benefits

Novo Nordisk’s oral amycretin tops Wegovy in obesity trial

Novo Nordisk looks set to add another string to Ozempic bow

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Novo Nordisk

Editor's Picks